

## **NextGen Group plc ("NextGen" or the "Company")**

### **Placing**

NextGen is pleased to announce that it has placed 200,000,000 ordinary shares through its Broker, Ellis Stockbrokers Limited, at 0.4p per share to raise £800,000, in order to provide development funding and general working capital purposes for the company, which the Directors believe will be sufficient for its current requirements.

A circular is to be dispatched to shareholders providing further information on the placing, which is being carried out on a non pre-emptive basis, and to convene the EGM for the purpose of granting the directors of the Company the necessary authorities to effect the placing. The Notice of EGM will be set out in the circular. Application will be made for admission of the new Ordinary Shares issued pursuant to the Placing to be admitted to trading on the AIM market of the London Stock Exchange, subject to shareholders' approval at the EGM. The new Ordinary Shares will rank *pari passu* with the existing ordinary shares of the Company.

For further details please contact:

Dr James G Heffernan  
CEO, NextGen Group PLC                      01480 420 979

Jonathan Wright/Nicola Marrin  
Seymour Pierce Limited                      020 7107 8000

Notes to Editors:

### **About NextGen Sciences**

NextGen Group PLC (LSE:NGG) is a provider of expert systems, services and reagents focused on enabling enhanced access to and understanding of the role of proteins in diagnosis and drug discovery. The expert systems are built out of NextGen's understanding of biological sciences and combine robotics, advanced engineering and rules based software in systems that range from partial to fully automated. NextGen also uses its systems and instruments to provide fee-for-service products under the Brand Name **contractexpress**<sup>™</sup> to the pharmaceutical and biotechnology industry as well as those in academic research.

NextGen Group PLC floated on the AIM market in London in December 2005 raising £2.4 million in an oversubscribed offering which included strong institutional investor support from Germany as well as in the UK.

Further details relating to NextGen Group PLC and its products can be found at [www.nextgensciences.com](http://www.nextgensciences.com)